Alpiropride
Appearance
(Redirected from Rivestel)
Clinical data | |
---|---|
Trade names | Revistel, Rivistel, or Rivestel |
Other names | Iristel; RIV-2093; RIV2093; RIV 2093; Riv 2093; Riv-2093; Riv2093 |
Drug class | Dopamine D2 receptor antagonist; Antihypertensive agent; Antimigraine agent |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.072.585 |
Chemical and physical data | |
Formula | C17H26N4O4S |
Molar mass | 382.48 g·mol−1 |
3D model (JSmol) | |
| |
|
Alpiropride (INN ; brand name Revistel, Rivistel, or Rivestel) is a dopamine D2 receptor antagonist of the benzamide group related to sulpiride.[1][2][3][4][5] It is described as an antihypertensive agent and has been marketed for use as an antimigraine medication in Portugal.[1][4][2] The drug was first described by 1980[1] and introduced for medical use by 1989.[4] It remained marketed in Portugal as late as 2000.[2]
References
[edit]- ^ a b c Elks, J. (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 33. ISBN 978-1-4757-2085-3. Retrieved 24 October 2024.
- ^ a b c Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 31. ISBN 978-3-88763-075-1. Retrieved 24 October 2024.
- ^ Milne, G.W.A. (2018). Drugs: Synonyms and Properties. Routledge Revivals. Taylor & Francis. p. 358. ISBN 978-1-351-78990-5. Retrieved 24 October 2024.
- ^ a b c Ong, Helen H.; Allen, Richard C. (1989). "Chapter 31. To Market, To Market -1988". Annual Reports in Medicinal Chemistry. Vol. 24. Elsevier. pp. 295–315. doi:10.1016/s0065-7743(08)60553-9. ISBN 978-0-12-040524-4. ISSN 0065-7743.
- ^ Current Medicinal Chemistry. Bentham Science Publishers. August 1997. p. 275. Retrieved 24 October 2024.